2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

staphylococcus aureus mrsa infection

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

1

Biochemical Assay Reagents

9

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14737
    Ceftaroline fosamil
    2 Publications Verification

    TAK-599; PPI0903

    		 Bacterial Antibiotic Infection
    Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection .
    Ceftaroline fosamil
  • HY-A0097
    Teicoplanin
    1 Publications Verification

    Antibiotic MDL-507; MDL-507

    		 Bacterial Antibiotic Infection
    Teicoplanin is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .
    Teicoplanin
  • HY-16764
    Avarofloxacin

    JNJ-Q2

    		 Bacterial Antibiotic Infection Inflammation/Immunology
    Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial agent being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia with oral activity. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections .
    Avarofloxacin
  • HY-112959
    Telavancin

    TD-6424

    		 Antibiotic Bacterial Infection
    Telavancin (TD-6424) is a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). Telavancin disrupts cell membrane integrity, can be used for research of complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria .
    Telavancin
  • HY-B1924
    Norvancomycin monohydrochloride
    1 Publications Verification

    N-Demethylvancomycin monohydrochloride; NVCM monohydrochloride

    		 Bacterial Infection
    Norvancomycin hydrochloride is a cell wall synthesis inhibitor targeting peptidoglycan precursors of Gram-positive bacteria and cannot pass the blood-brain barrier. Norvancomycin hydrochloride can competitively bind to peptidoglycan precursors, irreversibly inhibit bacterial cell wall synthesis, and exert antibacterial activity. Norvancomycin hydrochloride is mainly used in the study of Gram-positive bacterial infections, especially infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Norvancomycin hydrochloride can also be incorporated into the bionic calcium phosphate coating of titanium implants to enhance antibacterial activity and inhibit postoperative orthopedic infections .
    Norvancomycin monohydrochloride
  • HY-14737A
    Ceftaroline fosamil hydrate
    2 Publications Verification

    TAK-599 hydrate; PPI0903 hydrate

    		 Antibiotic Bacterial Infection
    Ceftaroline fosamil hydrate is a potent cephalosporin antibiotic. Ceftaroline fosamil hydrateshows broad-spectrum activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative organisms. Ceftaroline fosamil hydrate has anti-infective activity, and can be used for the research of complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) .
    Ceftaroline fosamil hydrate
  • HY-N15451
    Deoxytopsentin

    		Pyruvate Kinase Infection
    Deoxytopsentin (compound 5) is a marine bisindole alkaloid and also a MRSA pyruvate kinase inhibitor. Deoxytopsentin exists in sponges. Deoxytopsentin exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus strains in vitro .
    Deoxytopsentin
  • HY-108569
    nTZDpa

    		Antibiotic Bacterial PPAR Infection
    nTZDpa is an antibiotic. nTZDpa is a PPARG partial agonist. nTZDpa has antibacterial activity. nTZDpa is effective against growing and persistent Staphylococcus aureus by lipid bilayer disruption .
    nTZDpa
  • HY-N3515
    Multicaulisin

    		Bacterial Infection
    Multicaulisin, a new Diels-Alder type adduct from Morus multicaulis roots, potently effects against Staphylococcus aureus (MRSA) isolates. Multicaulisin is an antibacterial agent and has the potential for MRSA infections research .
    Multicaulisin
  • HY-14738
    Ceftaroline fosamil (inner)

    TAK-599 free acid; PPI0903 free acid

    		 Bacterial Antibiotic Infection
    Ceftaroline fosamil (inner) (TAK-599 free acid), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil (inner) can be used for the research of MRSA infection .
    Ceftaroline fosamil (inner)
  • HY-N10834
    (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol

    		Bacterial Infection
    (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is an antibacterial compound. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be isolated from the roots of Atractylodes japonica. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol has anti-methicillin-resistant Staphylococcus aureus (MRSA) activity with MIC values of 4-32 μg/mL. (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol can be used for the research of bacterial infection . (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (6E,12E)-Tetradecadiene-8,10-diyne-1,3-diol
  • HY-157482
    EBP-59

    		Bacterial Infection
    EBP-59 is a bacterial inhibitor with antibiofilm activity against Gram-positive bacteria. EBP-59 is effective against Staphylococcus aureus and MRSA (methicillin–resistant staphylococcus aureus). EBP-59 can be used to study bacterial infections .
    EBP-59
  • HY-178912
    Anti-MRSA agent 39

    		Reactive Oxygen Species (ROS) Bacterial ClpP Infection Inflammation/Immunology
    Anti-MRSA agent 39 is an orally active ClpX modulator that binds Staphylococcus aureus caseinolytic protease X (SaClpX) with high affinity (Kd = 3.6 μM). Anti-MRSA agent 39 exerts antibacterial effects through temperature-dependent inhibition of cell division. Anti-MRSA agent 39 elicits profound metabolic dysregulation in methicillin-resistant Staphylococcus aureus (MRSA), manifesting as significantly reduced ATP levels, elevated reactive oxygen species (ROS), and decreased NAD+/NADH ratio, and accelerates bacterial lysis rates in MRSA ATCC 33591. Anti-MRSA agent 39 significantly increases the proportion of MRSA cells in the mitotic phase, and the cells exhibit obvious morphological abnormalities. Anti-MRSA agent 39 can be used for the study of invasive MRSA infections .
    Anti-MRSA agent 39
  • HY-14737R
    Ceftaroline fosamil (Standard)

    TAK-599 (Standard); PPI0903 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection
    Ceftaroline fosamil (Standard) is the analytical standard of Ceftaroline fosamil. This product is intended for research and analytical applications. Ceftaroline fosamil (TAK-599), a cephalosporin derivative, is an N-phosphono proagent of anti-methicillin-resistant Staphylococcus aureus (MRSA) T-91825. Ceftaroline fosamil can be used for the research of MRSA infection[1][2][3].
    Ceftaroline fosamil (Standard)
  • HY-A0097A
    Teicoplanin sodium

    Antibiotic MDL-507 sodium; MDL-507 sodium

    		 Antibiotic HIV SARS-CoV Infection
    Teicoplanin sodium is a glycopeptide antibiotic indicated for use in serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus aureus.Teicoplanin sodium shows antiviral activity for HIV-1, SARS-CoV1 and SARS-CoV2. Teicoplanin sodium shows anti-MRSA activity .
    Teicoplanin sodium
  • HY-178949
    MRSA antibiotic 3

    		Antibiotic Bacterial DNA/RNA Synthesis Infection
    MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models .
    MRSA antibiotic 3
  • HY-173478
    OSUAB-0284

    		Topoisomerase Bacterial Antibiotic Infection
    OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .
    OSUAB-0284
  • HY-N16460
    Albomycin δ2

    		Antibiotic Bacterial Infection
    Albomycin δ2 is a siderophore-antibiotic conjugate targeting bacterial ribosomes (MIC: 0.0625 μg/mL against S. pneumoniae, 0.125 μg/mL against MRSA). Albomycin δ2 is promising for research of Streptococcus pneumoniae and Staphylococcus aureus infections .
    Albomycin δ2
  • HY-175301
    TH16

    		Bacterial Reactive Oxygen Species (ROS) Infection
    TH16 is an antibacterial agent (MIC=2 μg/mL against methicillin-resistant Staphylococcus aureus, MRSA). TH16 disrupts bacterial cytoplasmic membrane integrity, elevating intracellular reactive oxygen species (ROS) levels to induce bacterial death. TH16 is promising for research of bacterial infection .
    TH16
  • HY-174985
    Anti-MRSA agent 32

    		Bacterial Infection
    Anti-MRSA agent 32 (Compound 26) is an orally active and selective SaClpP (Staphylococcus aureus ClpP protease) activator with an EC50 value of 0.98 μM. Anti-MRSA agent 32 activates SaClpP to abnormally degrade bacterial proteins, inhibiting the proliferation of Staphylococcus aureus. Anti-MRSA agent 32 promotes wound healing in a murine skin infection model. Anti-MRSA agent 32 is promising for research of infectious diseases such as methicillin-resistant Staphylococcus aureus (MRSA) infections .
    Anti-MRSA agent 32
  • HY-175338
    Anti-MRSA agent 34

    		Bacterial Infection
    Anti-MRSA agent 34 (Compound 6) is an antimicrobial agent targeting methicillin-resistant Staphylococcus aureus (MRSA) (MIC=14 μg/mL). Anti-MRSA agent 34 is promising for research of microbial infection .
    Anti-MRSA agent 34
  • HY-174273
    Antibacterial agent 280

    		Bacterial Infection
    Antibacterial agent 280 (Compound 7af) is an antibacterial agent targeting methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). Antibacterial agent 280 is promising for research of is promising for research of S. aureus infections .
    Antibacterial agent 280
  • HY-Z8025
    Deprodone

    		Bacterial Infection Inflammation/Immunology
    Deprodone is an active compound. Deprodone inhibits key processes such as bacterial cell wall synthesis by interacting with the hydrolase and transferase proteins of methicillin-resistant Staphylococcus aureus (MRSA). Deprodone is used in research on anti-MRSA infection, inflammatory skin disorders, bowel disease, and fatty acid metabolism disorders .
    Deprodone
  • HY-173225
    MRSA/VRE-IN-1

    		Bacterial Infection
    MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .
    MRSA/VRE-IN-1
  • HY-178493
    Anti-MRSA agent 37

    		Bacterial Infection
    Anti-MRSA agent 37 (Compound 5B) is an antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA) (MIC=0.25-0.5 μg/mL). Anti-MRSA agent 37 inhibits biofilm formation, disrupts cell wall integrit, attacks cell membrane and induces oxidative stress. Anti-MRSA agent 37 is promising for research of MRSA-related diseases such as skin infections .
    Anti-MRSA agent 37
  • HY-173240
    IPMCL-28b

    		Bacterial Infection
    IPMCL-28b is an antibacterial agent targeting the bacterial cell membrane. Its minimum inhibitory concentration (MIC) against Staphylococcus aureus ATCC 25923 is 1.56 μg/mL, and the MIC against methicillin-resistant Staphylococcus aureus (MRSA) is 6.25 μg/mL. IPMCL-28b is expected to be used in the research of the anti-infection field .
    IPMCL-28b
  • HY-179059
    Anti-MRSA agent 40

    		Bacterial Reactive Oxygen Species (ROS) Infection
    Anti-MRSA agent 40 (Compound 7-8) is a potent agent against Methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 40 exhibits significant antibacterial activity against MRSA2 and S. aureus ATCC 29213, with its MIC values being 1 μg/mL. Anti-MRSA agent 40 causes depolarization of the cell membrane, damages membrane integrity, and simultaneously increases the level of ROS within MRSA2, ultimately leading to cell lysis and death. Anti-MRSA agent 40 shows significant efficacy in the MRSA2 skin abscess model. Anti-MRSA agent 40 can be used for research on anti-MRSA infections .
    Anti-MRSA agent 40
  • HY-156122
    DHFR-IN-8

    		Dihydrofolate reductase (DHFR) Bacterial Infection
    DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=15.6 ng/mL) in mouse models of systemic infection and thigh infection .
    DHFR-IN-8
  • HY-172826
    Anti-MRSA agent 26

    		Bacterial Infection
    Anti-MRSA agent 26 is a potent anti-MRSA agent with MIC <0.015 μg/mL. Anti-MRSA agent 26 has superior activity against a broad range of Gram-positive pathogens and shows no cytotoxicity in three mammalian cell lines (Caco-2, DU-145 and MDCKII MDR1 cells) at 10 μM. Anti-MRSA agent 26 has a robust TAP pharmacophore and an excellent antibacterial activity in Staphylococcus aureus skin infection mice model .
    Anti-MRSA agent 26
  • HY-173318
    Anti-MRSA agent 25

    		Bacterial Infection
    Anti-MRSA agent 25 (Compound 10c) is an antibacterial agent with a MIC of 0.25 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Anti-MRSA agent 25 exerts its antibacterial activity by inhibiting biofilm formation, disrupting the cell wall (interacting with peptidoglycan and lipoteichoic acids), acting on the cell membrane (causing depolarization, increasing permeability, and disrupting integrity), reducing metabolic activity, interfering with cellular redox homeostasis, and binding to DNA. Anti-MRSA agent 25 is expected to be used in the research of the anti-infection field .
    Anti-MRSA agent 25
  • HY-175295A
    Anti-MRSA agent 33 iodide

    		Bacterial Reactive Oxygen Species (ROS) Infection
    Anti-MRSA agent 33 iodide is an anti-Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) agent, with MIC values of 2-4 μg/mL. Anti-MRSA agent 33 iodide demonstrates effective biofilm eradication and minimal cytotoxicity toward mammalian cells. Anti-MRSA agent 33 iodide specifically binds to phosphatidylglycerol (PG) on bacterial membranes, leading to membrane disruption, excessive production of ROS, and metabolic collapse, ultimately resulting in bacterial cell death. Anti-MRSA agent 33 iodide reduces bacterial load in a murine skin infection model .
    Anti-MRSA agent 33 iodide
  • HY-174158
    Antibacterial agent 270

    		Bacterial Infection
    Antibacterial agent 270 (Compound 3e) is an antibacterial agent that acts on bacterial membrane components phosphatidylglycerol (PG), cardiolipin (CL), and bacterial DNA. Antibacterial agent 270 disrupts bacterial membrane structure and binds to DNA to interfere with genetic information transmission. Antibacterial agent 270 is promising for research of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) .
    Antibacterial agent 270
  • HY-16764A
    Acorafloxacin hydrochloride

    JNJ-Q2 hydrochloride

    		 Bacterial Infection Inflammation/Immunology
    Acorafloxacin hydrochloride (JNJ-Q2 hydrochloride) is a broad-spectrum fluoroquinolone anti-bacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia . Acorafloxacin hydrochloride is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value . Acorafloxacin hydrochloride has potential for study of methicillin-resistant Staphylococcus aureus (MRSA) infections .
    Acorafloxacin hydrochloride
  • HY-113718
    DS21412020

    		Bacterial Topoisomerase DNA/RNA Synthesis Infection
    DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin (HY-121544)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics .
    DS21412020
  • HY-182033
    ClpP agonist 1

    		Bacterial ClpP Infection
    ClpP agonist 1 is a Staphylococcus aureus ClpP (SaClpP) agonist with an EC50 of 1.44 μM, Kd values of 2.95 μM (isothermal titration calorimetry) and 18 μM (bio-layer interferometry), and a low drug resistance frequency. ClpP agonist 1 reduces bacterial load, shrinks infected area and improves histopathological outcomes in a mouse skin infection model. ClpP agonist 1 can be used for the research of Methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA) skin infections .
    ClpP agonist 1
  • HY-175795
    Tyrosinase activator-1

    		Tyrosinase Bacterial Antibiotic Infection
    Tyrosinase activator-1 (Compound 7A) is a Tyrosinase activator. Tyrosinase activator-1 significant antibacterial activity against gram-positive bacteria, such as MRSA, Staphylococcus aureus ATCC653 and Enterococcus faecium with MICs of 12.5-20  μM. Tyrosinase activator-1 activates tyrosinase by competitively occupying the binding site of L-DOPA on the surface of tyrosinase without interfering with the substrate binding at the active center. Tyrosinase activator-1 can be used for bacterial infections and antibiotics development research .
    Tyrosinase activator-1
  • HY-156123
    DHFR-IN-9

    		Dihydrofolate reductase (DHFR) Bacterial Infection Cancer
    DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days) .
    DHFR-IN-9
  • HY-183291
    Antibacterial agent 343

    		Bacterial DNA/RNA Synthesis DNA Alkylator/Crosslinker Reactive Oxygen Species (ROS) Penicillin-binding protein (PBP) Infection
    Antibacterial agent 343 (Compound 47) is an Antibacterial agent. Antibacterial agent 343 binds to the allosteric site of PBP2a to open its active site. Antibacterial agent 343 disrupts bacterial cell membranes, leading to protein leakage. Antibacterial agent 343 interacts with DNA and inhibits replication and transcription. Antibacterial agent 343 induces ROS accumulation. Antibacterial agent 343 exhibits antibacterial activity against MRSA, Staphylococcus aureus, and Enterococcus faecalis. Antibacterial agent 343 can be used for the research of methicillin-resistant Staphylococcus aureus infections .
    Antibacterial agent 343
  • HY-N18878
    Ambigol C

    		Bacterial Endogenous Metabolite Parasite Infection
    Ambigol C is an ambigol, Antibacterial agent and Antimalarial agent. Ambigol C is isolated from Fischerella ambigua 108b. Ambigol C exhibits selective antibacterial activity against Gram-positive Staphylococcus aureus strains (including MRSA) with MIC values of 0.98-3.91 μg/mL. Ambigol C also shows potent antibacterial activity against B. megaterium, and possesses weak antimalarial and trypanocidal effects. Ambigol C can be used in the research of bacterial infections, plasmodial infections and trypanosomal infections .
    Ambigol C
  • HY-N17297
    Leotiomycene C

    		Fungal Infection
    Leotiomycene C is an isoprenylated bisresorcinol natural product present in the freshwater fungus Helotiales sp. Leotiomycene C inhibits the quorum sensing system of methicillin (HY-121544)-resistant Staphylococcus aureus (MRSA), with an IC₅₀ of 6.3-12.5 μM. Leotiomycene C is applicable to research related to MRSA infections .
    Leotiomycene C
  • HY-10391
    E-3709

    		Bacterial Infection
    E3709 is an antibacterial agent. E3709 exhibits significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridia, and diphtheroids. E3709 can be used for research related to Gram-positive bacterial infections .
    E-3709
  • HY-105401
    J-114870

    		Bacterial Infection
    J-114870 is a bacterial penicillin-binding protein (PBPs) inhibitor. J-114870 is effective against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci (MRCoNS). J-114870 can be used for research on bacterial infections .
    J-114870
  • HY-185443
    UCP1172

    		Bacterial Dihydrofolate reductase (DHFR) Infection
    UCP1172 is an antibacterial (Antibacterial) agent and Dihydrofolate reductase inhibitor, with an IC50 of 0.0089 μM against Staphylococcus aureus DfrB, 0.22 μM against DfrG, 0.41 μM against DfrA, and 0.030 μM against DfrK. UCP1172 potently inhibits the growth of MRSA/MSSA isolates carrying dfrG and dfrK (MIC values of 0.3125-0.625 μg/mL), shows weak activity against MRSA carrying dfrA (MIC of 5 μg/mL), and exerts extremely potent inhibitory effects on wild-type S. aureus ATCC 43300 (MIC of 0.0098 μg/mL). UCP1172 can be used in studies related to tuberculosis and Staphylococcus aureus infections .
    UCP1172
  • HY-180191
    Anti-MRSA agent 42

    		Bacterial Reactive Oxygen Species (ROS) DNA/RNA Synthesis Infection
    Anti-MRSA agent 42 (Compound 6d) is an anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. Anti-MRSA agent 42 shows strong inhibitory effects on MRSA standard strains and 11 clinical isolates with MIC values of 0.25-0.5 μg/mL. Anti-MRSA agent 42 has low hemolytic activity and minimal cytotoxicity toward mammalian cells. Anti-MRSA agent 42 can suppress biofilm formation, compromise the cell wall, and disrupt the cytoplasmic membrane, which are accompanied by membrane depolarization, enhanced permeability, and loss of membrane integrity. Anti-MRSA agent 42 can induce ROS production and bind to DNA grooves, interfering with nucleic acid function. Anti-MRSA agent 42 can be used for the research of MRSA infection .
    Anti-MRSA agent 42
  • HY-179611
    LP-03

    		Bacterial Infection
    LP-03 is an antibacterial agent with selective activity against Methicillin-resistant Staphylococcus aureus (MRSA). Its minimum inhibitory concentration (MIC) is 6.2 μM. LP-03 has an inhibitory effect on biofilm formation, but it is unable to effectively remove the formed biofilms. LP-03 can enhance membrane permeability, disrupt the membrane structure of MRSA cells, and does not cause significant membrane depolarization. LP-03 has no hemolytic toxicity and shows low mammalian cell toxicity. It can be used for research on MRSA infections .
    LP-03
  • HY-179405
    Antibacterial agent 301

    		Bacterial Infection
    Antibacterial agent 301 (compound 14c) is a pyridine-amide pleuromutilin derivative with broad-spectrum antibacterial and pronounced antimycoplasmal activity. Antibacterial agent 301 inhibits peptidyl transferase center (PTC), breaks down biofilms, and disrupts cell membranes in multidrug-resistant (MDR) bacteria. Antibacterial agent 301 exhibits activity in a systemic methicillin-resistant Staphylococcus aureus (MRSA) infection mouse model. Antibacterial agent 301 can be used for MDR bacterial infection research .
    Antibacterial agent 301
  • HY-N19220
    Radiclonic acid

    		Bacterial Endogenous Metabolite Antibiotic Infection Cancer
    Radiclonic acid acts as an Antibacterial agent, anticancer agent, and root growth promoter. Radiclonic acid is isolable from fungi of the genus Penicillium. Radiclonic acid exhibits antibacterial activity against MRSA with a MIC of 3.13 μg/mL. Radiclonic acid shows anticancer activity against esophageal cancer, bladder cancer, and liver cancer. Radiclonic acid promotes root growth in Chinese cabbage seedlings. Radiclonic acid is inactive against pancreatic cancer and cervical cancer. Radiclonic acid can be used in research related to Staphylococcus aureus infection, bladder cancer, esophageal cancer, and liver cancer .
    Radiclonic acid
  • HY-181835
    AgrC-IN-1

    		Bacterial Infection
    AgrC-IN-1 is an AgrC inhibitor with an IC50 of 3.5 μM against Staphylococcus aureus AgrC. AgrC-IN-1 competitively binds to AgrC, inhibiting its autophosphorylation activity in Staphylococcus aureus. AgrC-IN-1 inhibits quorum sensing in Staphylococcus aureus, blocking virulence factor production. AgrC-IN-1 can be used for the research of Staphylococcus aureus infections .
    AgrC-IN-1
  • HY-69174
    1-Amino-2,5-anhydro-1-deoxy-D-mannitol

    		Bacterial
    1-Amino-2,5-anhydro-1-deoxy-D-mannitol is a potent antibacterial compound with antibacterial activity against a variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The application potential of 1-Amino-2,5-anhydro-1-deoxy-D-mannitol lies in its ability to effectively combat common drug-resistant bacterial infections. 1-Amino-2,5-anhydro-1-deoxy-D-mannitol may become an emerging antibacterial agent in clinical inhibition.
    1-Amino-2,5-anhydro-1-deoxy-D-mannitol
  • HY-181939
    Antibacterial agent 329

    		Bacterial Infection
    Antibacterial agent 329 (Compound 9c) is an antibacterial agent. Antibacterial agent 329 inhibits the activity of MraY. Antibacterial agent 329 exhibits antibacterial activity against Escherichia coli K12 and Bacillus subtilis W23 with a MIC of 16 μg/mL, but shows no activity against Pseudomonas fluorescens Pf-5. Antibacterial agent 329 exerts antibacterial activity against Acinetobacter baumannii 19606, Staphylococcus aureus MRSA USA300 JE2, Enterobacter cloacae 19434, Klebsiella pneumoniae 700603 and Enterococcus faecium 19434, with MIC values of 8, 8, 16-32, 16-32 and 16 μg/mL, respectively, while it shows no activity against Pseudomonas aeruginosa NCTC 13437 .
    Antibacterial agent 329

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: